Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)
Condition: HER2 Negative Breast Cancer Not Immediately Operated Intervention: Drug: Ribociclib Oral Tablet Sponsor: Centre Antoine Lacassagne Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials
